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Historical Background 
The clinical use of immune serum globu- 
lin has had a relatively long history span- 
ning over three decades. This has been 
comprehensively reviewed by Dwyer. 14 
The principal breakthrough which resulted 
in the isolation of immune serum globulin 
or gamma globulin was the alcohol frac- 
tionation of serum proteins as developed 
by Cohn and his colleagues.12 This pro- 
cedure allows for the selective precipita- 
tion of gamma globulins from serum by 
the addition of 25% cold ethanol and this 
component is designated Cohn fraction II. 
Because reconstituted Cohn fraction II 
caused serious systemic reactions when 
given intravenously, its use has been 
solely restricted to intramuscular adminis- 
tration until the recent advent of intrave- 
nous immune globulin (IVIG). 
Although early use of gamma globulin 
included a role as an antimicrobial agent 
particularly during World War II when 
antibiotics, such as penicillin, were in 
very short supply, it subsequently found 
additional military application when given 
for the prophylaxis of infectious hepatitis 
A in U.S. troops abroad. 27 The defini- 
tive role of gamma globulin for antibody 
replacement therapy was described by Dr. 
Ogden Bruton, an army physician who 
identified the first case of primary immu- 
nodeficiency disease in a young boy. 6 
This patient was diagnosed as having hy- 
pogammaglobulinemia (which later was 
categorized as infantile, X-linked or Bru- 
ton's agammaglobulinemia) and was suc- 
cessfully treated with i.m. gamma 
globulin replacement therapy. Subse- 
quently, i.m. gamma globulin became the 
drug of choice for the therapy of antibody 
deficiency syndromes, although fresh fro- 
zen plasma has also been used. 22 
The introduction to the U.S. of an in- 
travenous form of immunoglobulin in 
1981 permitted significant improvement 
in the management of immunodeficiency 
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ntravenous immune globulin (IVIG) 
first became available for patient use 
in the United States in 1981. Since 
that time, seven IVIG products have been 
approved by the FDA for clinical 
use. 59'67 The officially licensed indica- 
tions currently are replacement therapy in 
primary immunodeficiency disease as 
well as the treatment of idiopathic throm- 
bocytopenic purpura and low-grade B-cell 
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malignancies. The 1990 (National Insti- 
tutes of Health) NIH Consensus Develop- 
ment Conference on Intravenous 
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